Stock Events

Stock Events

Bolt Biotherapeutics 

$4.00
15
+$0.10+2.57% 19:28 Today

Statistics

Day High
4
Day Low
3.85
52W High
7.2
52W Low
3.13
Volume
7,118
Avg. Volume
24,120
Mkt Cap
7.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-7.1
-4.86
-2.62
-0.38
Expected EPS
-3.5175
Actual EPS
N/A

Financials

-433.74%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.7MRevenue
-33.38MNet Income

Analyst Ratings

14.50Average Price Target
The highest estimate is 22.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BOLT. It's not an investment recommendation.
Apple
7
AAPL
Tesla
7
TSLA
Coca-Cola
7
KO
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, which is a platform that can be used for cancer immunotherapy, competing with Bolt's immune-stimulating antibody conjugates.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech, similar to Moderna, works on mRNA-based therapies and has a strong focus on personalized cancer vaccines, directly competing with Bolt's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio of oncology products, including cell therapies and antibody-drug conjugates, offering competitive alternatives to Bolt's therapies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse oncology portfolio, including bispecific antibodies and CAR-T therapies, which could compete with Bolt's antibody-based therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals develops a range of biologic drugs, including those for cancer, with technologies that could rival Bolt's antibody conjugate platform.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech arm, is a leader in oncology with a wide range of cancer treatments, including ADCs and immunotherapies, competing with Bolt's offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong focus on oncology, with a portfolio that includes immunotherapies and targeted therapies, posing competition to Bolt's cancer treatment approaches.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio, including immunotherapies and targeted treatments, which compete with Bolt's development of novel cancer therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis has a diverse oncology segment, including CAR-T cell therapy, radioligand therapy, and targeted therapies, offering competitive options to Bolt's technology.

About

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Show more...
CEO
William Quinn
Employees
23
Country
United States
ISIN
US0977022039
WKN
000A419U9

Listings

F
DE
6LP0.F
STU
DE
6LP0.STU
MU
DE
6LP0.MU
XNAS
US
BOLT

0 Comments

Share your thoughts

FAQ

What is Bolt Biotherapeutics stock price today?▼
The current price of BOLT is $4.00 USD — it has increased by +2.57% in the past 24 hours. Watch Bolt Biotherapeutics stock price performance more closely on the chart.
What is Bolt Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Bolt Biotherapeutics stocks are traded under the ticker BOLT.
Is Bolt Biotherapeutics stock price growing?▼
BOLT stock has risen by +3.28% compared to the previous week, the month change is a -0.25% fall, over the last year Bolt Biotherapeutics has showed a -18.6% decrease.
What is Bolt Biotherapeutics market cap?▼
Today Bolt Biotherapeutics has the market capitalization of 7.7M
When is the next Bolt Biotherapeutics earnings date?▼
Bolt Biotherapeutics is going to release the next earnings report on November 05, 2026.
What were Bolt Biotherapeutics earnings last quarter?▼
BOLT earnings for the last quarter are -4.57 USD per share, whereas the estimation was -3.39 USD resulting in a -34.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bolt Biotherapeutics revenue for the last year?▼
Bolt Biotherapeutics revenue for the last year amounts to 7.7M USD.
What is Bolt Biotherapeutics net income for the last year?▼
BOLT net income for the last year is -33.38M USD.
How many employees does Bolt Biotherapeutics have?▼
As of September 04, 2026, the company has 23 employees.
In which sector is Bolt Biotherapeutics located?▼
Bolt Biotherapeutics operates in the Health & Wellness sector.
When did Bolt Biotherapeutics complete a stock split?▼
The last stock split for Bolt Biotherapeutics was on June 09, 2025 with a ratio of 1:20.
Where is Bolt Biotherapeutics headquartered?▼
Bolt Biotherapeutics is headquartered in REDWOOD CITY, United States.